Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study

Barbara Grube, Pee-Win Chong, Felix Alt, Ralf Uebelhack, Barbara Grube, Pee-Win Chong, Felix Alt, Ralf Uebelhack

Abstract

Background: Litramine (IQP-G-002AS) was shown to be effective and safe for weight loss in overweight and obese subjects. However, long-term effectiveness on maintenance of body weight loss has yet to be ascertained.

Objective: To assess effect of Litramine on maintenance of body weight loss.

Methods: A double-blind, randomised, placebo-controlled trial on overweight and obese patients was conducted over two sites in Germany for 24 weeks. Subjects with documented previous weight loss of 3% over the last 3-6 months were randomised to groups given either Litramine (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight in verum group, where maintenance is defined as ≤1% weight gain.

Results: Subjects who were taking Litramine lost significantly more body weight compared to the subjects taking placebo who gained weight instead (-0.62 ± 1.55 kg versus 1.62 ± 1.48 kg, p < 0.001). More importantly, 92% of subjects in Litramine group were able to maintain their body weight after initial weight loss, versus 25% in placebo group. No serious adverse events were reported throughout.

Conclusion: Litramine is effective and safe for long-term body weight maintenance. Trial Registration. This trial is registered with Clinicaltrials.gov identifier: NCT01505387.

Figures

Figure 1
Figure 1
CONSORT diagram on study flow.

References

    1. World Health Organisation (WHO) Obesity and overweight. Factsheet. 2014;(311)
    1. Haslam D. W., James W. P. T. Obesity. The Lancet. 2005;366(9492):1197–1209. doi: 10.1016/s0140-6736(05)67483-1.
    1. Arnold M., Pandeya N., Byrnes G., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. The Lancet Oncology. 2015;16(1):36–46. doi: 10.1016/S1470-2045(14)71123-4.
    1. Branca D., Nikogosian H., Lobstein T., editors. The Challenge of Obesity in the WHO European Region and the Strategies for Response: Summary. Copenhagen, Denmark: WHO Regional Office for Europe; 2007.
    1. Hammond R. A., Levine R. The economic impact of obesity in the United States. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2010;3:285–295. doi: 10.2147/DMSOTT.S7384.
    1. Dobbs R., Sawers C., Thompson F., et al. Overcoming Obesity: An Initial Economic Analysis. McKinsey Global Institute; 2014.
    1. Jensen M. D., Ryan D. H., Apovian C. M., et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Journal of the American College of Cardiology. 2014;63(25):2985–3023. doi: 10.1016/j.jacc.2013.11.004.
    1. Kroeger C. M., Hoddy K. K., Varady K. A. Impact of weight regain on metabolic disease risk: a review of human trials. Journal of Obesity. 2014;2014:8. doi: 10.1155/2014/614519.614519
    1. Rosenheck R. Fast food consumption and increased caloric intake: a systematic review of a trajectory towards weight gain and obesity risk. Obesity Reviews. 2008;9(6):535–547. doi: 10.1111/j.1467-789x.2008.00477.x.
    1. Schröder H., Fïto M., Covas M. I. Association of fast food consumption with energy intake, diet quality, body mass index and the risk of obesity in a representative Mediterranean population. British Journal of Nutrition. 2007;98(6):1274–1280. doi: 10.1017/s0007114507781436.
    1. Tsigos C., Hainer V., Basdevant A., et al. Management of obesity in adults: European clinical practice guidelines. Obesity Facts. 2008;1(2):106–116. doi: 10.1159/000126822.
    1. Uebelhack R., Busch R., Alt F., Beah Z.-M., Chong P.-W. Effects of cactus fiber on the excretion of dietary fat in healthy subjects: a double blind, randomized, placebo-controlled, crossover clinical investigation. Current Therapeutic Research—Clinical and Experimental. 2014;76:39–44. doi: 10.1016/j.curtheres.2014.02.001.
    1. Grube B., Chong P.-W., Lau K.-Z., Orzechowski H.-D. A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study. Obesity. 2013;21(1):58–64. doi: 10.1038/oby.2012.165.
    1. International Association for the Study of Obesity. Overweight and Obesity in the EU. London, UK: International Association for the Study of Obesity; 2008.
    1. Hill A. J., Rogers P. J., Blundell J. E. Techniques for the experimental measurement of human eating behaviour and food intake: a practical guide. International Journal of Obesity. 1995;19(6):361–375.
    1. Burton-Freeman B. Dietary fiber and energy regulation. Journal of Nutrition. 2000;130(2, supplement):272S–275S.
    1. Blundell J. E., Burley V. J. Satiation, satiety and the action of fibre on food intake. International Journal of Obesity. 1987;11(supplement 1):9–25.
    1. Johansson K., Neovius K., DeSantis S. M., Rössner S., Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obesity Reviews. 2009;10(5):564–575. doi: 10.1111/j.1467-789X.2009.00581.x.
    1. Cheung B. M. Y., Cheung T. T., Samaranayake N. R. Safety of antiobesity drugs. Therapeutic Advances in Drug Safety. 2013;4(4):171–181. doi: 10.1177/2042098613489721.
    1. Torp-Pedersen C., Caterson I., Coutinho W., et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. European Heart Journal. 2007;28(23):2915–2923. doi: 10.1093/eurheartj/ehm217.
    1. EMEA. European Medicines Agency recommends suspension of marketing authorisation for sibutramine. 2010, .
    1. FDA. FDA Drug Safety Communication: FDA Recommends against the Continued Use of Meridia (Sibutramine) 2010. .
    1. MHRA. Europe wide suspension of Marketing Authorisation for Acomplia (rimonabant) 2009, .
    1. Dombrowski S. U., Knittle K., Avenell A., Araújo-Soares V., Sniehotta F. F. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. British Medical Journal. 2014;348 doi: 10.1136/bmj.g2646.g2646
    1. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167–172. doi: 10.1016/s0140-6736(97)11509-4.
    1. EFSA Panel on Dietetic Products-Nutrition and Allergies (NDA) Guidance on the scientific requirement for health claims related to appetite ratings, weight management, and blood glucose concentration. EFSA Journal. 2012;10(3, article 2604) doi: 10.2903/j.efsa.2012.2604.
    1. Torgerson J. S., Hauptman J., Boldrin M. N., Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161. doi: 10.2337/diacare.27.1.155.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner